LATEST NEWS
CinDome Pharma, a CinRx portfolio company, presented a poster at the 2023 Digestive Disease Week (DDW) Conference.
CinRx Pharma Announces First Participant Dosed in CinDome’s Phase 2 Study of Deudomperidone (CIN-102) for the Treatment of Diabetic Gastroparesis.
CinRx Pharma Announces First Participant Dosed in CinDome’s Phase 2 Study of Deudomperidone (CIN-102) for the Treatment of Diabetic Gastroparesis.
CinCor Pharma, Inc. today announced that it has entered into a definitive agreement with AstraZeneca under which AstraZeneca has agreed to acquire CinCor.
CinRx Pharma announced today that Gavin Samuels, M.D., M.B.A has assumed the role of Chief Business Officer.
CinRx Pharma announced the first study participant has been dosed in CinFina’s Phase 1 multiple ascending dose (MAD) study of CIN-109.
